ArticleFrontiers in immunology2026
HAMSIAA protects cyclophosphamide induced immunosuppression by modulating gut homeostasis and purine metabolism.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dietary supplementation with functional starches serves as a promising intervention strategy for immune regulation, yet the immunomodulatory efficacy and underlying mechanisms of newly developed modified starch derivatives remain to be further explored. In this study, a cyclophosphamide (CTX) induced secondary immunodeficiency mouse model was adopted to investigate the immunoregulatory effects of indole 3 acetylated high amylose maize starch derivative (HAMSIAA). Methods: Mice were fed a basal diet supplemented with 0.5% or 1% HAMSIAA for nine consecutive days, with CTX administered starting on day 7. Immune organ injury, splenic CD4⁺/CD8⁺ T cell balance, serum immunoglobulins, intestinal barrier integrity, gut microbiota composition and purine related metabolome were assessed. Results: HAMSIAA attenuated CTX triggered damage to immune organs, maintained the splenic CD4⁺/CD8⁺ T cell balance, and increased serum levels of Immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM). In addition, HAMSIAA improved intestinal barrier integrity and modulated gut microbiota composition, as evidenced by changes in the Bacillota/Bacteroidota (B/B) ratio and a reduction in Pseudomonadota abundance. Metabolomic analyses further revealed that HAMSIAA was associated with modulation of the purine salvage pathway, including downregulation of hypoxanthine guanine phosphoribosyltransferase (HGPRT) and altered levels of metabolites such as inosine and xanthine, which may contribute to its immunoprotective effects. Discussion: Collectively, the present findings suggest that HAMSIAA is a promising functional food ingredient for the prophylactic mitigation of chemotherapy induced immunosuppression, and provide support for its translational application in the field of immunonutrition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.